Market
How many new board members will Senti Biosciences appoint by the end of 2025?
3
Resolution / Starting Odds
No new appointments • 25%
1 new member • 25%
2 new members • 25%
3 or more new members • 25%
Senti Biosciences official announcements or press releases
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
Other changes • 25%
Dana White leaves the board • 25%
Additional Trump allies join the board • 25%
No significant changes • 25%
Major overhaul • 25%
Other • 25%
No changes • 25%
Minor changes • 25%
Charlie Songhurst • 25%
John Elkann • 25%
Dana White • 25%
Equal influence • 25%
1 new species • 25%
2 new species • 25%
More than 3 new species • 25%
3 new species • 25%
3-5 members • 25%
0-2 members • 25%
9 or more members • 25%
6-8 members • 25%
Addition of financial experts • 25%
Other changes • 25%
No significant changes • 25%
Addition of new tech leaders • 25%
Charlie Songhurst • 25%
Dana White • 25%
John Elkann • 25%
None leaves • 25%
1-2 Members Change • 25%
3-4 Members Change • 25%
5 or More Members Change • 25%
No Change • 25%
No significant changes • 25%
Other leadership changes • 25%
Board reshuffle • 25%
CEO change • 25%
Other • 25%
Tech industry leader • 25%
Academic expert • 25%
Government official • 25%
Minor changes • 25%
Acquisition does not happen • 25%
No changes • 25%
Major changes • 25%